Combination Therapy with Renin-Angiotensin-aldosterone Receptor Blockers for Hypertension: How Far Have We Come?

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2008 Feb 8

PMID 18256579

Citations 13

Authors

Matthew R Weir

George L Bakris

Affiliations

Soon will be listed here.

Abstract

In a large number of patients with hypertension, > or =2 antihypertensive agents are required to achieve blood pressure (BP) goals. There is good rationale for initial combination therapy based on clinical trials demonstrating that achievement of BP goals within a reasonably short period of time results in fewer cardiovascular events. One approach to attaining BP goals and improving medication adherence is fixed-dose combination therapy, the use of which dates back to the 1960s. Given some of the advantages of renin-angiotensin-aldosterone system (RAAS) blockers in patients with heart disease, kidney disease, and diabetes, many combinations include either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. In most studies, however, thiazide diuretics were necessary to achieve goal BP. Calcium channel blockers have also been used in combination with angiotensin-converting enzyme inhibitors to lower BP. Studies are now under way to determine the relative benefits of an RAAS blocker/diuretic compared with an RAAS blocker/calcium channel blocker as initial therapy.

Citing Articles

Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management.

Narita K, Hoshide S, Kario K J Clin Med. 2023; 12(23).

PMID: 38068278 PMC: 10707551. DOI: 10.3390/jcm12237226.

Response surface analyses of antihypertensive effects of angiotensin receptor blockers and amlodipine or hydrochlorothiazide combination therapy in patients with essential hypertension.

Cho M, Oh E, Ahn B, Yoon M Transl Clin Pharmacol. 2023; 31(3):154-166.

PMID: 37810629 PMC: 10551747. DOI: 10.12793/tcp.2023.31.e15.

Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide - which is the better alternative? A meta-analysis.

Filipova E, Dineva S, Uzunova K, Pavlova V, Kalinov K, Vekov T Syst Rev. 2020; 9(1):195.

PMID: 32838806 PMC: 7445912. DOI: 10.1186/s13643-020-01457-9.

Retinal Neurovascular Impairment in Patients with Essential Hypertension: An Optical Coherence Tomography Angiography Study.

Peng Q, Hu Y, Huang M, Wu Y, Zhong P, Dong X Invest Ophthalmol Vis Sci. 2020; 61(8):42.

PMID: 32725211 PMC: 7425736. DOI: 10.1167/iovs.61.8.42.

Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter,....

Oh G, Lee H, Chung W, Youn H, Cho E, Sung K Clin Hypertens. 2017; 23:18.

PMID: 28879040 PMC: 5584029. DOI: 10.1186/s40885-017-0074-0.

References

Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K . Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006; 29(12):2592-7. DOI: 10.2337/dc06-1373. View

Connor J, Rafter N, Rodgers A . Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2005; 82(12):935-9. PMC: 2623099. DOI: /S0042-96862004001200010. View

Nathan S, Pepine C, Bakris G . Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension. 2005; 46(4):637-42. DOI: 10.1161/01.HYP.0000184541.24700.c7. View

Stergiou G, Makris T, Papavasiliou M, Efstathiou S, Manolis A . Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens. 2005; 23(4):883-9. DOI: 10.1097/01.hjh.0000163159.22116.ab. View

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G . 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25(6):1105-87. DOI: 10.1097/HJH.0b013e3281fc975a. View

Julius S, Kjeldsen S, Weber M, Brunner H, Ekman S, Hansson L . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-31. DOI: 10.1016/S0140-6736(04)16451-9. View

Andreadis E, Tsourous G, Marakomichelakis G, Katsanou P, Fotia M, Vassilopoulos C . High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens. 2005; 19(6):491-6. DOI: 10.1038/sj.jhh.1001843. View

Weir M, Ferdinand K, Flack J, Jamerson K, Daley W, Zelenkofske S . A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension. 2005; 46(3):508-13. DOI: 10.1161/01.HYP.0000180457.82483.6b. View

Bakris G, Weir M . Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003; 5(3):202-9. PMC: 8101800. DOI: 10.1111/j.1524-6175.2002.2041.x. View

10.

Messerli F, Oparil S, Feng Z . Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000; 86(11):1182-7. DOI: 10.1016/s0002-9149(00)01199-1. View

11.

Jamerson K, Bakris G, Dahlof B, Pitt B, Velazquez E, Gupte J . Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16(2):80-6. DOI: 10.1080/08037050701395571. View

12.

Sapienza S, Sacco P, Floyd K, DiCesare J, Doan Q . Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther. 2003; 25(6):1872-87. DOI: 10.1016/s0149-2918(03)80174-1. View

13.

Weir M, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R . Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007; 9(2):103-12. PMC: 8110071. DOI: 10.1111/j.1524-6175.2007.06415.x. View

14.

Berlowitz D, Ash A, HICKEY E, Friedman R, Glickman M, Kader B . Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998; 339(27):1957-63. DOI: 10.1056/NEJM199812313392701. View

15.

Kjeldsen S, Os I, Hoieggen A, Beckey K, Gleim G, Oparil S . Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs. 2005; 5(1):17-22. DOI: 10.2165/00129784-200505010-00003. View

16.

Wachtell K, Lehto M, Gerdts E, Olsen M, Hornestam B, Dahlof B . Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005; 45(5):712-9. DOI: 10.1016/j.jacc.2004.10.068. View

17.

Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J . Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365(9455):217-23. DOI: 10.1016/S0140-6736(05)17741-1. View

18.

Lacourciere Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B . Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind,.... Clin Ther. 2005; 27(7):1013-21. DOI: 10.1016/j.clinthera.2005.07.010. View

19.

Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

20.

Bellet M, Sassano P, Guyenne T, Corvol P, Menard J . Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine. Br J Clin Pharmacol. 1987; 24(4):465-72. PMC: 1386308. DOI: 10.1111/j.1365-2125.1987.tb03199.x. View